Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Raises $17M to Market Optical Mapping System

Premium

This story was originally published Sept. 27

OpGen, a commercial provider of optical restriction-mapping technology, has raised $17 million in Series B financing.

The financing adds to $23.6 million that the company raised in a Series A round in 2007 (IS 9/21/2007). The Series B was led by jVen Capital with participation from the company's other major investors, including CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical, and Versant Ventures. In addition, Evan Jones, the managing member of jVen Capital, has been named executive chairman of OpGen's board of directors.

OpGen's commercial optical mapping system, which was launched this June for microbial genome analysis, is an automated technology for generating maps that can be used in strain typing, comparative genomics, and sequence assembly.

The new funding will support marketing for the technology, dubbed the Argus Optical Mapping System. It will also "fuel our efforts to expand into new markets, including the development of new applications that will complement sequencing technologies and help facilitate rapid completion of large genome mapping and finishing technologies currently under development at the company," OpGen's CEO Douglas White said in a statement.

According to the company, the Argus system will have a wide range of applications in fields such as biodefense, outbreak management, agriculture, and clinical microbiology.

OpGen's customers include biodefense organizations, genomic research centers, academic institutions, clinical research organizations, and biotechnology companies.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.